These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26044980)

  • 1. Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs.
    McCreary AC; Newman-Tancredi A
    Curr Pharm Des; 2015; 21(26):3725-31. PubMed ID: 26044980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
    Newman-Tancredi A
    Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
    J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation.
    Schreiber R; Newman-Tancredi A
    Neurobiol Learn Mem; 2014 Apr; 110():72-80. PubMed ID: 24423786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism.
    McCreary AC; Jones CA
    Curr Pharm Des; 2010; 16(5):516-21. PubMed ID: 19909230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
    Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
    Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    J Clin Psychopharmacol; 2015 Jun; 35(3):220-7. PubMed ID: 25822479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
    Bruins Slot LA; De Vries L; Newman-Tancredi A; Cussac D
    Eur J Pharmacol; 2006 Mar; 534(1-3):63-70. PubMed ID: 16497294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.
    Ohno Y
    CNS Neurosci Ther; 2011 Feb; 17(1):58-65. PubMed ID: 21091640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?
    Bantick RA; Deakin JF; Grasby PM
    J Psychopharmacol; 2001 Mar; 15(1):37-46. PubMed ID: 11277607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
    Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.
    Haleem DJ
    Behav Pharmacol; 2015 Feb; 26(1-2):45-58. PubMed ID: 25503261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.
    Newman-Tancredi A; Assié MB; Leduc N; Ormière AM; Danty N; Cosi C
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):341-56. PubMed ID: 15707540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonergic mechanisms as targets for existing and novel antipsychotics.
    Meltzer HY
    Handb Exp Pharmacol; 2012; (212):87-124. PubMed ID: 23129329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P; Newman-Tancredi A; Loock T; Cussac D
    Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonergic approaches in the development of novel antipsychotics.
    Jones CA; McCreary AC
    Neuropharmacology; 2008 Nov; 55(6):1056-65. PubMed ID: 18621404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology.
    Gogos A; Bogeski M; van den Buuse M
    Behav Pharmacol; 2008 Sep; 19(5-6):548-61. PubMed ID: 18690109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic effect of quetiapine on cognitive impairment associated with 5-HT1A presynaptic receptor involved schizophrenia.
    Han D; Shi S; Luo H
    J Integr Neurosci; 2019 Sep; 18(3):245-251. PubMed ID: 31601072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.